MT Newswires
Abbott Laboratories Closes Acquisition of Exact Sciences
📈
AI Sentiment
Highly Positive
8/10
- Home
- ABT
as of 03-24-2026 3:52pm EST
$103.85
$1.00
-0.95%
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
| Founded: | 1888 | Country: | United States |
| Employees: | 115000 | City: | ABBOTT PARK |
| Market Cap: | 183.3B | IPO Year: | 2006 |
| Target Price: | $139.38 | AVG Volume (30 days): | 7.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 3.72 | EPS Growth: | -51.31 |
| 52 Week Low/High: | $105.27 - $137.49 | Next Earning Date: | 04-15-2026 |
| Revenue: | $44,328,000,000 | Revenue Growth: | 5.67% |
| Revenue Growth (this year): | 8.9% | Revenue Growth (next year): | 7.39% |
| P/E Ratio: | 28.59 | Index: | |
| Free Cash Flow: | 7.4B | FCF Growth: | +16.44% |
Stock Insider Trading Activity of Abbott Laboratories (ABT)
Salvadori Daniel Gesua Sive
Sell
EVP AND GROUP PRESIDENT
ABT Mar 2, 2026
Avg Cost/Share
$115.58
Shares
885
Total Value
$102,288.30
Owned After
146,377
SEC Form 4
Morrone Louis H.
Sell
EXECUTIVE VICE PRESIDENT
ABT Mar 2, 2026
Avg Cost/Share
$115.58
Shares
1,144
Total Value
$132,223.52
Owned After
76,843
SEC Form 4
Moreland Mary K
Sell
EXECUTIVE VICE PRESIDENT
ABT Mar 2, 2026
Avg Cost/Share
$115.58
Shares
613
Total Value
$70,850.54
Owned After
104,291
SEC Form 4
MCCOY JOHN A. JR.
Sell
VICE PRESIDENT AND CONTROLLER
ABT Mar 2, 2026
Avg Cost/Share
$115.58
Shares
585
Total Value
$67,614.30
Owned After
24,628
SEC Form 4
Shroff Eric
Sell
Senior Vice President
ABT Mar 2, 2026
Avg Cost/Share
$115.58
Shares
709
Total Value
$81,946.22
Owned After
39,164
SEC Form 4
Cushman Elizabeth C.
Sell
EVP, GC AND SECRETARY
ABT Mar 2, 2026
Avg Cost/Share
$115.58
Shares
263
Total Value
$30,397.54
Owned After
38,573
SEC Form 4
STARKS DANIEL J
Buy
Director
ABT Feb 4, 2026
Avg Cost/Share
$108.74
Shares
10,000
Total Value
$1,087,331.40
Owned After
6,733,784
Ford Robert B
Buy
CHAIRMAN AND CEO
ABT Jan 23, 2026
Avg Cost/Share
$107.13
Shares
18,800
Total Value
$2,013,966.92
Owned After
216,203
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Salvadori Daniel Gesua Sive | ABT | EVP AND GROUP PRESIDENT | Mar 2, 2026 | Sell | $115.58 | 885 | $102,288.30 | 146,377 | |
| Morrone Louis H. | ABT | EXECUTIVE VICE PRESIDENT | Mar 2, 2026 | Sell | $115.58 | 1,144 | $132,223.52 | 76,843 | |
| Moreland Mary K | ABT | EXECUTIVE VICE PRESIDENT | Mar 2, 2026 | Sell | $115.58 | 613 | $70,850.54 | 104,291 | |
| MCCOY JOHN A. JR. | ABT | VICE PRESIDENT AND CONTROLLER | Mar 2, 2026 | Sell | $115.58 | 585 | $67,614.30 | 24,628 | |
| Shroff Eric | ABT | Senior Vice President | Mar 2, 2026 | Sell | $115.58 | 709 | $81,946.22 | 39,164 | |
| Cushman Elizabeth C. | ABT | EVP, GC AND SECRETARY | Mar 2, 2026 | Sell | $115.58 | 263 | $30,397.54 | 38,573 | |
| STARKS DANIEL J | ABT | Director | Feb 4, 2026 | Buy | $108.74 | 10,000 | $1,087,331.40 | 6,733,784 | |
| Ford Robert B | ABT | CHAIRMAN AND CEO | Jan 23, 2026 | Buy | $107.13 | 18,800 | $2,013,966.92 | 216,203 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 22, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 22, 2026 · 100% conf.
AI Prediction SELL
1D
-0.71%
$107.82
Act: -0.75%
5D
-1.68%
$106.77
Act: -2.30%
20D
-0.02%
$108.57
Act: +3.33%
Price: $108.59 Prob +5D: 0% AUC: 1.000
0001628280-26-002982
abt-202601220000001800FALSENew York Stock ExchangeCHX00000018002026-01-222026-01-220000001800exch:XCHI2026-01-222026-01-220000001800exch:XNYS2026-01-222026-01-22
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2026 Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in charter)
Illinois1-218936-0698440 (State or other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification  No.)
100 Abbott Park Road Abbott Park, Illinois 60064-6400 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: (224) 667-6100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s) Name of Each Exchange on Which Registered
Common Shares, Without Par ValueABTNew York Stock Exchange NYSE Texas
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02    Results of Operations and Financial Condition On January 22, 2026, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2025. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, legal reserves, fair value adjustments to the contingent consideration related to business acquisitions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
Item 9.01Â Â Â Â Financial Statements and Exhibits
Exhibit No.Exhibit
99.1 Press Release dated January 22, 2026 (furnished pursuant to Item 2.02).
104Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ABBOTT LABORATORIES
Date: January 22, 2026By:/s/ Philip P. Boudreau Philip P. Boudreau Executive Vice President, Finance and Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 15, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 15, 2025
0001628280-25-045049
abt-202510150000001800FALSENew York Stock ExchangeCHX00000018002025-10-152025-10-150000001800exch:XCHI2025-10-152025-10-150000001800exch:XNYS2025-10-152025-10-15
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 15, 2025 Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in charter)
Illinois1-218936-0698440 (State or other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification  No.)
100 Abbott Park Road Abbott Park, Illinois 60064-6400 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: (224) 667-6100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s) Name of Each Exchange on Which Registered
Common Shares, Without Par ValueABTNew York Stock Exchange NYSE Texas
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02    Results of Operations and Financial Condition On October 15, 2025, Abbott Laboratories announced its results of operations for the third quarter 2025. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, fair value adjustments to the contingent consideration related to business acquisitions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
Item 9.01Â Â Â Â Financial Statements and Exhibits
Exhibit No.Exhibit
99.1 Press Release dated October 15, 2025 (furnished pursuant to Item 2.02).
104Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ABBOTT LABORATORIES
Date: October 15, 2025 By:/s/ Philip P. Boudreau Philip P. Boudreau Executive Vice President, Finance and Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Jul 17, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 17, 2025
0001628280-25-035135
abt-202507170000001800FALSENew York Stock ExchangeChicago Stock Exchange, Inc.00000018002025-07-172025-07-170000001800exch:XCHI2025-07-172025-07-170000001800exch:XNYS2025-07-172025-07-17
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 17, 2025 Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in charter)
Illinois1-218936-0698440 (State or other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification  No.)
100 Abbott Park Road Abbott Park, Illinois 60064-6400 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: (224) 667-6100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s) Name of Each Exchange on Which Registered
Common Shares, Without Par ValueABTNew York Stock Exchange Chicago Stock Exchange, Inc.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02    Results of Operations and Financial Condition On July 17, 2025, Abbott Laboratories announced its results of operations for the second quarter 2025. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, fair value adjustments to the contingent consideration related to business acquisitions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
Item 9.01Â Â Â Â Financial Statements and Exhibits
Exhibit No.Exhibit
99.1 Press Release dated July 17, 2025 (furnished pursuant to Item 2.02).
104Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ABBOTT LABORATORIES
Date: July 17, 2025 By:/s/ Philip P. Boudreau Philip P. Boudreau Executive Vice President, Finance and Chief Financial Officer
Latest Abbott Laboratories News
ABT Breaking Stock News: Dive into ABT Ticker-Specific Updates for Smart Investing
Simply Wall St.
Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness
📊
AI Sentiment
Positive
6/10
Insider Monkey
Is Abbott Laboratories (ABT) A Good Stock To Buy Now?
📊
AI Sentiment
Positive
7/10
TipRanks
Transformational Opportunities: UBS Suggests 2 Longevity Stocks to Buy as the $8T Aging Boom Accelerates
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Sector Update: Health Care Stocks Retreat Late Afternoon
📉
AI Sentiment
Negative
3/10
Compare ABT vs Leading Stocks
See how ABT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABT Abbott Laboratories - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.